Cellectis publishes corporate presentation on allogeneic CAR-T pipeline, TALEN gene-editing platform
CLLS•Corporate presentation highlights pipeline, cash position and manufacturing footprint
Cellectis published a corporate presentation outlining its allogeneic CAR-T pipeline and TALEN gene-editing platform.
- Cellectis outlined 4 ongoing allogeneic CAR-T clinical trials, including 2 pivotal Phase 2 studies and 2 Phase 1 studies.
- Cash position of USD 169 million as of June 30, 2026; expected runway into Q4 2027.
- Lasme-cel pivotal Phase 2 first interim analysis expected in Q4 2026; eti-cel Phase 1 full dataset expected in Q4 2026.
- Presentation highlighted TALEN gene-editing platform positioning on safety, precision, efficiency, versatility.
- Manufacturing footprint centered on Paris, France, and Raleigh, North Carolina, supporting end-to-end in-house production.
